REVOLADE Enables Treatment by
The Route Patients Prefer
Patients prefer once-daily oral therapy vs injections1
- These results are based on the responses of 1,491 patients who participated in a patient and physician survey on immune thrombocytopenia (ITP) conducted in 13 countries1
Patient Preference for Oral Therapy Was
Confirmed in International Studies2-4
Confirmed in International Studies2-4
- These 3 studies assessed outcomes before and after patients switched (N=178) between the thrombopoietin receptor agonists (TPO-RAs) romiplostim and REVOLADE
- Also evaluated were the reasons patients were switched from one therapy to another2-4
- Additionally, of the patients who switched therapy due to experiencing platelet fluctuations, 92% (23/25) switched from romiplostim to REVOLADE2-4
References:
1. Data on file. 2. Carpenedo M, Cantoni S, Mazzucconi MG, et al. Sequential use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Poster presented at: The 22nd European Hematology Association Congress; June 24, 2017; Madrid, Spain. Abstract P722. 3. Lakhwani S, Perera M, Fernández-Fuertes F, et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol. 2017;99(4):372-377. 4. Khellaf M, Viallard J-F, Hamidou M, et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881-887.
